The self-expanding A-Flux device is implanted in the coronary sinus to increase pressure on the venous side of the heart and improve perfusion in smaller vessels.
Radiologists, meanwhile, took to social media to criticize the endeavor, noting that the generative AI company lacks clinical evidence to back its marketing claims.
The proportion of radiologists performing some (>0%) IR-related work declined from 70% in 2008 down to 50% by 2023, according to new research published in JVIR.
One of the largest food retailers in the world—and the fourth biggest in this country—got itself into hot water with the U.S. Department of Justice for allegedly cheating on drug prices it charges to federal healthcare programs.
Tamin Naber, MD, was charged with simple assault for biting a former employee at his medical practice who was suing him for wrongful termination. The incident occurred in November 2025.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
Arizona Attorney General Kris Mayes had accused the Scottsdale-based radiology group of issuing delayed refunds after allegedly using questionable upfront billing practices.
The self-expanding A-Flux device is implanted in the coronary sinus to increase pressure on the venous side of the heart and improve perfusion in smaller vessels.
